BIIBBiogen Inc.
193.76USD+2.26%Mkt Cap: 28.61B USDP/E: 20.83Last update: 2026-05-22

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…

loading…
Indicators:|

Key Statistics

Company
Market Cap28.61B USD
Enterprise Value30.25B USD
Revenue (TTM)9.94B USD
Gross Profit7.49B USD
Net Income (TTM)1.29B USD
Revenue/Share67.70 USD
Last Price193.76 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS09062X1037
Valuation
P/E (Trailing)20.83
P/E (Forward)11.42
PEG3.94
EV/EBITDA8.61
EV/Revenue3.04
P/S2.81
P/B1.50
EPS (TTM)9.30
EPS (Forward)16.59
52W Range
121.0586% of range205.97
52W High205.97 USD
52W Low121.05 USD
Profitability
Gross Margin75.69%
Oper. Margin22.90%
EBITDA Margin35.38%
Profit Margin13.07%
ROE7.08%
ROA4.39%
Growth
Revenue Growth1.90%
Earnings Growth31.10%
Cash Flow & Leverage
Operating CF2.20B USD
CapEx (TTM)235.40M USD
FCF Margin19.28%
FCF Yield6.70%
Net Debt2.28B USD
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.36
Current Ratio3.06
Quick Ratio2.02
Book Value/Sh126.37 USD
Cash/Share29.01 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split3:1
Split DateJan 18, 2001
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)219.27 USD
Target Range150.00 USD300.00 USD
# Analysts29
Ownership
Shares Out.147.64M
Float147.18M
Insiders0.17%
Institutions96.60%
Short Interest
Short Ratio3.2d
Short % Float3.38%
Short % Out.3.03%
Shares Short4.48M
Short (prev mo.)3.83M
Technical
SMA 50185.54 (+4.4%)
SMA 200168.89 (+14.7%)
Beta0.20
S&P 52W Chg28.31%
Avg Vol (30d)1.20M
Avg Vol (10d)1.37M
Technical Indicators
RSI (14)
MACD
MACD Signal
MACD Hist.
BB Upper
BB Middle
BB Lower
BB Width
ATR (14)
Vol Ratio (20d)